|Bid||0.00 x 2900|
|Ask||0.00 x 900|
|Day's Range||76.54 - 77.48|
|52 Week Range||64.27 - 89.54|
|PE Ratio (TTM)||46.10|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||2.28 (2.93%)|
|1y Target Est||87.87|
Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Gilead Sciences Inc. ( GILD) has risen by more than 18% since the start of May, and it looks likes shares may still be heading even higher. Analysts have been upping their earnings and revenue outlook for the biotech company since it reported blowout second-quarter results at the end of July, and now see the stock rising by nearly 13% based on the average price targets. Analysts have increased their average price on the stock to $87.40 since the company reported results, up from a prior target of $85.84.
Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.
BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.
Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?
Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.
Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. The Innovative Health segment reported a rise of 3% in revenue to ~$4.58 billion, while the Essential Health segment reported a ~14% fall in revenue to $1.65 billion. The rise in the Innovative Health segment was driven by a 5% rise in vaccines sales, a 5% rise in oncology sales, a 33% rise in inflammation and immunology sales, and a 1% rise in consumer healthcare sales.
Health care stocks have made a sharp break to the upside so far in the third quarter, leading the S&P 500 Index (SPX) and outpacing tech stocks in the process. As measured by both the S&P 500 Health Care Index and the Health Care Select Sector SPDR ETF ( XLV), health care stocks closed Monday just 1.8% below their record highs set in January. "Overall they look quite good," said Matt Maley, equity strategist at Miller Tabak, in an interview with CNBC.
Pfizer (PFE) reports its revenue into two business segments: Innovative Health and Essential Health. As we discussed in the previous article, Pfizer reported a YoY (year-over-year) rise of 4% in its top line to $13.5 billion in the second quarter compared to $12.9 million during the second quarter of 2017. This outperformance was driven by a 2% favorable foreign exchange impact and a 2% rise in operating revenue in the second quarter.